Vaccine-related poliovirus shedding in trivalent polio vaccine and human immunodeficiency virus status: analysis from under five children

Table 6 Duration and proportions of participants shedding vaccine after immunization verses the age of the study subjects

Parameters	Total, n = 26 (%)	< 12 months	13–24 months	25–48 months	49–60 months
2 weeks
PV 1	9 (34.6)	1 (3.8)	2 (7.7)	4 (15.4)	2 (7.7)
PV 2	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)
PV 3	10 (38.5)	3 (11.5)	4 (15.4)	3 (11.5)	0 (0)
PV 1 + 2	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)
PV 1 + 3	3 (11.5)	0 (0)	2 (7.7)	1 (3.8)	0 (0)
PV 1 + 2+3	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)
PV 1 + 2 + 3 + NPEV	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)
4 weeks
PV 1	7 (26.9)	2 (7.7)	1 (3.8)	3 (11.5)	1 (3.8)
PV 2	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)
PV 3	10 (38.5)	2 (7.7)	5 (19.2)	3 (11.5)	0 (0)
PV 1 + 2	1 (3.8)	0 (0)	0 (0)	0 (0)	1 (3.8)
PV 1 + 3	5 (19.2)	0 (0)	2 (7.7)	3 (11.5)	0 (0)
PV 2 + 3	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)
PV 1 + 2 + 3	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)
PV 1 + 3 + NPEV	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)
6 weeks
Negative	24 (92.3)	4 (15.4)	8 (30.8)	10 (38.5)	2 (7.7)
PV 2	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)
NPEV	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)
8 weeks
Negative	25 (96.2)	4 (15.4)	8 (30.8)	11 (42.3)	2 (7.7)
NPEV	1 (3.8)	0 (0)	0 (0)	1 (3.8)	0 (0)

ISSN: 1756-0500